MIR-217 mediates the protective effects of the dopamine D2 receptor on fibrosis in human renal proximal tubule cells

Hypertension

Volumn 65, Issue 5, 2015, Pages 1118-1125

  Han, Fei ^a   Konkalmatt, Prasad ^b   Chen, Jianghua ^a   Gildea, John ^c   Felder, Robin A ^c   Jose, Pedro A ^b   Armando, Ines ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

microRNAs; receptor dopamine D2; transforming growth factors

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 1A; DOPAMINE 2 RECEPTOR; FIBRONECTIN; FIBRONECTIN 1; MICRORNA; MICRORNA 1265; MICRORNA 1290; MICRORNA 217; MICRORNA 224; MICRORNA 335; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 2; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; WNT5A PROTEIN; MESSENGER RNA; MIRN217 MICRORNA, HUMAN;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; WNT SIGNALING PATHWAY; ALLELE; BIOSYNTHESIS; CELL CULTURE; CONFOCAL MICROSCOPY; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOBLOTTING; KIDNEY DISEASE; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ALLELES; CELLS, CULTURED; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOBLOTTING; KIDNEY DISEASES; KIDNEY TUBULES, PROXIMAL; MICRORNAS; MICROSCOPY, CONFOCAL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84937399962     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.05096     Document Type: Article

References (34)

1. Zhang Y, Cuevas S, Asico LD, Escano C, Yang Y, Pascua AM, Wang X, Jones JE, Grandy D, Eisner G, Jose PA, Armando I. Deficient dopamine D2 receptor function causes renal inflammation independently of high blood pressure. PLoS One. 2012; 7: e38745. doi: 10.1371/journal. pone.0038745
2. Asghar M, Chugh G, Lokhandwala MF. Inflammation compromises renal dopamine D1 receptor function in rats. Am J Physiol Renal Physiol. 2009; 297: F1543-F1549. doi: 10.1152/ajprenal.00366.2009
3. Zhang MZ, Yao B, Wang S, Fan X, Wu G, Yang H, Yin H, Yang S, Harris RC. Intrarenal dopamine deficiency leads to hypertension and decreased longevity in mice. J Clin Invest. 2011; 121: 2845-2854. doi: 10.1172/JCI57324
4. Yang S, Yao B, Zhou Y, Yin H, Zhang MZ, Harris RC. Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury. Am J Physiol Renal Physiol. 2012; 302: F742-F749. doi: 10.1152/ajprenal.00583.2011
5. Zhang MZ, Yao B, Yang S, Yang H, Wang S, Fan X, Yin H, Fogo AB, Moeckel GW, Harris RC. Intrarenal dopamine inhibits progression of diabetic nephropathy. Diabetes. 2012; 61: 2575-2584. doi: 10.2337/db12-0046
6. Jiang X, Konkalmatt P, Yang Y, Gildea J, Jones JE, Cuevas S, Felder RA, Jose PA, Armando I. Single-nucleotide polymorphisms of the dopamine D2 receptor increase inflammation and fibrosis in human renal proximal tubule cells. Hypertension. 2014; 63: e74-e80. doi: 10.1161/HYPERTENSIONAHA.113.02569
7. Shao W, Zhang SZ, Tang M, et al. Suppression of neuroinflammation by astrocytic dopamine D2 receptors via aB-crystallin. Nature. 2013; 494: 90-94. doi: 10.1038/nature11748
8. Thomas GN, Tomlinson B, Critchley JA. Modulation of blood pressure and obesity with the dopamine D2 receptor gene TaqI polymorphism. Hypertension. 2000; 36: 177-182
9. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet. 2003; 12: 205-216
10. Prasad P, Kumar KM, Ammini AC, Gupta A, Gupta R, Thelma BK. Association of dopaminergic pathway gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes. BMC Genet. 2008; 9: 26. doi: 10.1186/1471-2156-9-26
11. Pottier N, Cauffiez C, Perrais M, Barbry P, Mari B. FibromiRs: translating molecular discoveries into new anti-fibrotic drugs. Trends Pharmacol Sci. 2014; 35: 119-126. doi: 10.1016/j.tips.2014.01.003
12. Castro NE, Kato M, Park JT, Natarajan R. Transforming growth factor β1 (TGF-β1) enhances expression of profibrotic genes through a novel signaling cascade and microRNAs in renal mesangial cells. J Biol Chem. 2014; 289: 29001-29013. doi: 10.1074/jbc.M114.600783
13. Gildea JJ, McGrath HE, Van Sciver RE, Wang DB, Felder RA. Isolation, growth, and characterization of human renal epithelial cells using traditional and 3D methods. Methods Mol Biol. 2013; 945: 329-345. doi: 10.1007/978-1-62703-125-7-20
14. Ibarra FR, Armando I, Nowicki S, Carranza A, De Luca Sarobe V, Arrizurieta EE, Barontini M. Dopamine is metabolised by different enzymes along the rat nephron. Pflugers Arch. 2005; 450: 185-191. doi: 10.1007/s00424-005-1386-6
15. Kozell LB, Neve KA. Constitutive activity of a chimeric D2/D1 dopamine receptor. Mol Pharmacol. 1997; 52: 1137-1149
16. Oishi I, Suzuki H, Onishi N, Takada R, Kani S, Ohkawara B, Koshida I, Suzuki K, Yamada G, Schwabe GC, Mundlos S, Shibuya H, Takada S, Minami Y. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells. 2003; 8: 645-654
17. Vettori S, Gay S, Distler O. Role of MicroRNAs in Fibrosis. Open Rheumatol J. 2012; 6: 130-139. doi: 10.2174/1874312901206010130
18. Szeto CC, Ching-Ha KB, Ka-Bik L, Mac-Moune LF, Cheung-Lung CP, Gang W, Kai-Ming C, Kam-Tao LP. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis Markers. 2012; 33: 137-144. doi: 10.3233/DMA-2012-0914
19. Deng S, Zhu S, Wang B, et al. Chronic pancreatitis and pancreatic cancer demonstrate active epithelial-mesenchymal transition profile, regulated by miR-217-SIRT1 pathway. Cancer Lett. 2014; 355: 184-191. doi: 10.1016/j.canlet.2014.08.007
20. Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013; 58: 629-641. doi: 10.1002/hep.26369
21. Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I, Gunn A, Nakagawa Y, Shimano H, Todorov I, Rossi JJ, Natarajan R. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 2009; 11: 881-889. doi: 10.1038/ncb1897
22. Nishita M, Enomoto M, Yamagata K, Minami Y. Cell/tissue-Tropic functions of Wnt5a signaling in normal and cancer cells. Trends Cell Biol. 2010; 20: 346-354. doi: 10.1016/j.tcb.2010.03.001
23. Kumawat K, Menzen MH, Bos IS, Baarsma HA, Borger P, Roth M, Tamm M, Halayko AJ, Simoons M, Prins A, Postma DS, Schmidt M, Gosens R. Noncanonical WNT-5A signaling regulates TGF-β-induced extracellular matrix production by airway smooth muscle cells. FASEB J. 2013; 27: 1631-1643. doi: 10.1096/fj.12-217539
24. Li X, Yamagata K, Nishita M, Endo M, Arfian N, Rikitake Y, Emoto N, Hirata K, Tanaka Y, Minami Y. Activation of Wnt5a-Ror2 signaling associated with epithelial-To-mesenchymal transition of tubular epithelial cells during renal fibrosis. Genes Cells. 2013; 18: 608-619. doi: 10.1111/gtc.12064
25. Rashid ST, Humphries JD, Byron A, Dhar A, Askari JA, Selley JN, Knight D, Goldin RD, Thursz M, Humphries MJ. Proteomic analysis of extracellular matrix from the hepatic stellate cell line LX-2 identifies CYR61 and Wnt-5a as novel constituents of fibrotic liver. J Proteome Res. 2012; 11: 4052-4064. doi: 10.1021/pr3000927
26. Vuga LJ, Ben-Yehudah A, Kovkarova-Naumovski E, Oriss T, Gibson KF, Feghali-Bostwick C, Kaminski N. WNT5A is a regulator of fibroblast proliferation and resistance to apoptosis. Am J Respir Cell Mol Biol. 2009; 41: 583-589. doi: 10.1165/rcmb.2008-0201OC.
27. Chen Z, Xu L, Ye X, Shen S, Li Z, Niu X, Lu S. Polymorphisms of microRNA sequences or binding sites and lung cancer: a meta-Analysis and systematic review. PLoS One. 2013; 8: e61008. doi: 10.1371/journal.pone.0061008
28. Johnson MM, Michelhaugh SK, Bouhamdan M, Schmidt CJ, Bannon MJ. The transcription factor NURR1 exerts concentration-dependent effects on target genes mediating distinct biological processes. Front Neurosci. 2011; 5: 135. doi: 10.3389/fnins.2011.00135
29. Kim SY, Choi KC, Chang MS, Kim MH, Kim SY, Na YS, Lee JE, Jin BK, Lee BH, Baik JH. The dopamine D2 receptor regulates the development of dopaminergic neurons via extracellular signal-regulated kinase and Nurr1 activation. J Neurosci. 2006; 26: 4567-4576. doi: 10.1523/JNEUROSCI.5236-05.2006
30. McKnight AJ, Currie D, Maxwell AP. Unravelling the genetic basis of renal diseases; from single gene to multifactorial disorders. J Pathol. 2010; 220: 198-216. doi: 10.1002/path.2639
31. Garrett MR, Pezzolesi MG, Korstanje R. Integrating human and rodent data to identify the genetic factors involved in chronic kidney disease. J Am Soc Nephrol. 2010; 21: 398-405. doi: 10.1681/ASN.2009080881
32. Ma RC, Tam CH, Wang Y, Luk AO, Hu C, Yang X, Lam V, Chan AW, Ho JS, Chow CC, Tong PC, Jia W, Ng MC, So WY, Chan JC. Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes. JAMA. 2010; 304: 881-889. doi: 10.1001/jama.2010.1191
33. Xia Y, Entman ML, Wang Y. Critical role of CXCL16 in hypertensive kidney injury and fibrosis. Hypertension. 2013; 62: 1129-1137. doi: 10.1161/HYPERTENSIONAHA.113.01837
34. Köttgen A, Hwang SJ, Rampersaud E, Coresh J, North KE, Pankow JS, Meigs JB, Florez JC, Parsa A, Levy D, Boerwinkle E, Shuldiner AR, Fox CS, Kao WH. TCF7L2 variants associate with CKD progression and renal function in population-based cohorts. J Am Soc Nephrol. 2008; 19: 1989-1999. doi: 10.1681/ASN.2007121291